OncoMatch/Clinical Trials/NCT06642220
Ablative Radioembolization of Renal Cell Carcinoma Trial
Is NCT06642220 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Y-90 Selective Internal Radiation Therapy (SIRT) for renal cell carcinoma (rcc).
Treatment: Y-90 Selective Internal Radiation Therapy (SIRT) — Renal cell carcinoma (RCC), the most common type of kidney cancer, is typically treated with surgery; however, there is no established therapy for patients who are not surgical candidates and who have tumours greater than 4.0 cm in size. Selective internal radiation therapy (SIRT) or radioembolization using radioactive spheres containing 90-Yttrium (Y-90) is successful at treating large tumours with high doses of radiation within the liver and might be similarly effective for treating larger RCC tumours in patients, particularly those who are not surgical candidates. This prospective study will enroll 16 participants with RCC who are not candidates for surgery and treat them with Y-90 radioembolization using a high-dose therapy to see if it is an effective cancer therapy. Primary outcome will be RCC treatment response 1 year after the Y-90 radioembolization. Additionally, the safety, tolerability, and impact on kidney function of the therapy will be monitored for all participants. Patients will be followed for a total of 5 years to evaluate long-term outcome in cancer control and safety of the treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: kidney radiation therapy
Prior or concurrent kidney radiation therapy
Cannot have received: systemic immunotherapy
Prior or concurrent systemic immunotherapy/TKI
Cannot have received: tyrosine kinase inhibitor
Prior or concurrent systemic immunotherapy/TKI
Lab requirements
Blood counts
Hemoglobin ≥8.0 g/dL; ANC ≥1000 cells/µL; Platelets >50 × 10^9/L
Kidney function
Severely impaired renal function (GFR ≤ 30 mL/min/1.73m²) and not on dialysis [excluded]
Liver function
AST and ALT ≤2.5 × ULN (or ≤5 × ULN if presence of liver metastases); total bilirubin ≤3 × ULN; serum albumin ≥3.0 g/dL unless PT is within normal range
Cardiac function
Congestive heart failure with ejection fraction < 40% [excluded]
Adequate hepatic function, defined by the following laboratory results: AST and ALT ≤2.5 × ULN (or ≤5 × ULN if presence of liver metastases); total bilirubin ≤3 × ULN; serum albumin ≥3.0 g/dL unless PT is within normal range. Adequate hematologic function, defined by the following laboratory results: Hemoglobin ≥8.0 g/dL; ANC ≥1000 cells/µL; Platelets >50 × 10^9/L. Severely impaired renal function (GFR ≤ 30 mL/min/1.73m²) and not on dialysis [excluded]. Congestive heart failure with ejection fraction < 40% [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify